These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
252 related items for PubMed ID: 8700512
21. Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene. Hwang ES, Naeger LK, DiMaio D. Oncogene; 1996 Feb 15; 12(4):795-803. PubMed ID: 8632901 [Abstract] [Full Text] [Related]
22. CSF-1 activates MAPK-dependent and p53-independent pathways to induce growth arrest of hormone-dependent human breast cancer cells. Lee AW, Nambirajan S, Moffat JG. Oncogene; 1999 Dec 09; 18(52):7477-94. PubMed ID: 10602507 [Abstract] [Full Text] [Related]
23. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells. Gong J, Ammanamanchi S, Ko TC, Brattain MG. Cancer Res; 2003 Jun 15; 63(12):3340-6. PubMed ID: 12810668 [Abstract] [Full Text] [Related]
24. Heregulin-dependent autocrine loop regulates growth of K-ras but not erbB-2 transformed rat thyroid epithelial cells. Mincione G, Piccirelli A, Lazzereschi D, Salomon DS, Colletta G. J Cell Physiol; 1998 Aug 15; 176(2):383-91. PubMed ID: 9648926 [Abstract] [Full Text] [Related]
25. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells. Ram TG, Hosick HL, Ethier SP. J Cell Physiol; 2000 Jun 15; 183(3):301-13. PubMed ID: 10797304 [Abstract] [Full Text] [Related]
26. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Oncogene; 1999 Jan 14; 18(2):305-14. PubMed ID: 9927187 [Abstract] [Full Text] [Related]
27. Increased cdc2 and cdk2 kinase activity by retinoid X receptor gamma-mediated transcriptional down-regulation of the cyclin-dependent kinase inhibitor p21Cip1/WAF1 correlates with terminal differentiation of squamous cell carcinoma lines. Crowe DL, Shuler CF. Cell Growth Differ; 1998 Aug 14; 9(8):619-27. PubMed ID: 9716179 [Abstract] [Full Text] [Related]
28. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Oncogene; 2001 Jan 11; 20(2):147-55. PubMed ID: 11313944 [Abstract] [Full Text] [Related]
29. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification. Ram TG, Schelling ME, Hosick HL. Cell Growth Differ; 2000 Mar 11; 11(3):173-83. PubMed ID: 10768865 [Abstract] [Full Text] [Related]
30. Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine. Gollapudi L, Neet KE. J Neurosci Res; 1997 Aug 15; 49(4):461-74. PubMed ID: 9285522 [Abstract] [Full Text] [Related]
31. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells. Daly JM, Jannot CB, Beerli RR, Graus-Porta D, Maurer FG, Hynes NE. Cancer Res; 1997 Sep 01; 57(17):3804-11. PubMed ID: 9288791 [Abstract] [Full Text] [Related]
32. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage. Menendez JA, Mehmi I, Lupu R. Int J Oncol; 2005 Mar 01; 26(3):649-59. PubMed ID: 15703820 [Abstract] [Full Text] [Related]
33. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity. Coppock DL, Buffolino P, Kopman C, Nathanson L. Exp Cell Res; 1995 Nov 01; 221(1):92-102. PubMed ID: 7589260 [Abstract] [Full Text] [Related]
34. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC. Clin Cancer Res; 1999 Nov 01; 5(11):3653-60. PubMed ID: 10589783 [Abstract] [Full Text] [Related]
35. Transforming growth factor-beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1. Miyazaki M, Ohashi R, Tsuji T, Mihara K, Gohda E, Namba M. Biochem Biophys Res Commun; 1998 May 29; 246(3):873-80. PubMed ID: 9618305 [Abstract] [Full Text] [Related]
36. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells. Orend G, Hunter T, Ruoslahti E. Oncogene; 1998 May 29; 16(20):2575-83. PubMed ID: 9632134 [Abstract] [Full Text] [Related]
37. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells. Fiddes RJ, Janes PW, Sivertsen SP, Sutherland RL, Musgrove EA, Daly RJ. Oncogene; 1998 May 28; 16(21):2803-13. PubMed ID: 9652748 [Abstract] [Full Text] [Related]
38. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Soda G, Antonaci A, Bosco D, Nardoni S, Melis M. J Exp Clin Cancer Res; 1999 Sep 28; 18(3):363-7. PubMed ID: 10606183 [Abstract] [Full Text] [Related]
39. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Ravid D, Maor S, Werner H, Liscovitch M. Oncogene; 2005 Feb 17; 24(8):1338-47. PubMed ID: 15592498 [Abstract] [Full Text] [Related]
40. ErbB-3 mediates differential mitogenic effects of NDF/heregulin isoforms on mouse keratinocytes. Marikovsky M, Lavi S, Pinkas-Kramarski R, Karunagaran D, Liu N, Wen D, Yarden Y. Oncogene; 1995 Apr 06; 10(7):1403-11. PubMed ID: 7731691 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]